Financial Reports Latest Updates Industry Maps Economic Calendar

RHYTHM PHARMACEUTICALS, INC. (RYTM) Annual Reports

Q: Where can I read RHYTHM PHARMACEUTICALS, INC. (RYTM) annual reports?

Every year on this page links straight to the full text on SEC EDGAR. US annual reports are web pages (HTML) rather than PDFs, so you can read and search them in the browser. 3 filings are currently indexed.

Q: What is the difference between a 10-K and a 20-F?

A 10-K is the annual report of a US domestic issuer; a 20-F is filed by foreign private issuers (Taiwanese companies with US ADRs, such as TSMC, file 20-F). A 40-F applies to Canadian issuers under the MJDS.

RHYTHM PHARMACEUTICALS, INC. is listed on Nasdaq, classified by the SEC under Pharmaceutical Preparations (SIC 2834). This page indexes 3 annual reports, each linking to the full text on the SEC's EDGAR system.

Company profile

Exchange： Nasdaq
Fiscal year end： 12/31
SEC CIK： 1649904 →

Website：Official site ↗

Financial Highlights

FY2026 Q2 (quarterly, ended 2026-06-30)
	Current	Prior year	YoY
Revenue	$71.3M	$48.5M	+46.9%
Operating income	$-48.6M	$-45.3M	-7.2%
Net income	$-49.3M	$-46.6M	-5.7%
EPS (diluted)	$-0.73	$-0.75	+2.7%

Source: SEC EDGAR (XBRL company facts)

Financial history

Revenue & profit

Quarterly · In mn (USD)

Revenue 71.3 mn Net income -49.3 mn

Show table：Income statement

Item	2015Q4	2016Q1	2016Q2	2016Q3	2016Q4	2017Q1	2017Q2	2017Q3	2017Q4	2018Q1	2018Q2	2018Q3	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2
Revenue	—	—	—	—	0	—	—	—	0	—	—	—	0	—	—	—	0	—	—	—	0	0.04	0.27	1.03	1.82	1.50	9.07	4.28	8.79	11.5	19.2	22.5	24.2	26.0	29.1	33.3	41.8	32.7	48.5	51.3	57.3	60.1	71.3
Operating income	-10.6	—	—	-6.40	-8.37	-6.39	-6.75	-8.29	-11.0	-17.0	-15.0	-19.2	-27.1	-30.5	-44.1	-37.1	-34.2	-35.3	-31.9	-34.3	-35.1	-34.4	-40.4	-44.2	-51.0	-52.7	-45.1	-39.3	-42.1	-52.5	-46.6	-44.0	-41.3	-140	-40.5	-43.9	-41.3	-47.0	-45.3	-52.6	-47.1	-52.4	-48.5
Net income	-11.1	-5.38	-5.73	-6.39	-8.37	-6.36	-6.80	-10.0	-10.5	-16.5	-14.4	-17.7	-25.5	-29.0	-42.8	-36.0	-33.0	-34.2	-31.1	-33.8	-34.9	43.8	-35.4	-35.1	-42.9	-52.8	-45.0	-40.9	-42.5	-52.2	-46.7	-44.2	-41.6	-141	-32.3	-43.6	-43.3	-49.5	-46.6	-52.9	-47.5	-55.6	-49.3

Balance sheet

Quarterly · In mn (USD)

Total assets 437 mn Total liabilities 220 mn

Equity = assets − liabilities. Balance-sheet figures are period-end balances, not cumulative.

Show table：Balance sheet

Item	2015Q4	2016Q1	2016Q2	2016Q3	2016Q4	2017Q1	2017Q2	2017Q3	2017Q4	2018Q1	2018Q2	2018Q3	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2
Current assets	—	—	—	—	11.2	—	—	32.0	151	138	291	277	259	230	204	171	302	268	238	210	182	412	378	336	308	253	249	362	354	318	284	329	308	236	357	340	374	369	361	495	467	430	427
Total assets	—	—	—	—	12.3	—	—	34.8	152	139	292	278	260	237	211	178	309	274	243	215	187	422	388	356	330	285	278	390	382	346	310	354	333	259	382	364	392	387	373	507	480	442	437
Current liabilities	—	—	—	—	4.73	—	—	5.46	6.72	5.58	7.25	7.80	13.6	12.6	26.1	25.2	24.4	17.7	14.9	15.8	18.0	16.9	17.5	23.5	43.4	47.3	44.6	33.1	39.8	46.0	46.1	50.1	55.2	54.2	54.7	97.6	116	112	129	104	106	103	124
Total liabilities	—	—	—	—	5.04	—	—	5.71	6.95	5.79	7.43	8.09	13.9	16.0	29.4	28.4	27.5	20.7	17.7	18.5	20.6	41.3	36.7	33.6	45.4	49.1	82.0	108	118	126	128	157	163	197	202	211	228	224	239	211	210	205	220
Equity	-8.00	—	—	—	-32.7	—	—	-51.9	145	134	284	270	246	220	181	149	281	253	226	197	167	381	352	322	284	236	196	281	264	220	182	197	170	61.6	39.3	11.2	21.7	18.9	-11.9	149	139	123	103

Cash flow

Quarterly · In mn (USD)

Operating -9.15 mn Investing 14.0 mn Financing -1.16 mn

Positive = cash in, negative = cash out.

Show table：Cash flow statement

Item	2015Q4	2016Q1	2016Q2	2016Q3	2016Q4	2017Q1	2017Q2	2017Q3	2017Q4	2018Q1	2018Q2	2018Q3	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2
Operating	-6.98	—	—	-17.0	-6.18	-7.02	-6.14	-8.42	-7.88	-11.7	-12.5	-16.9	-21.0	-31.4	-25.6	-33.6	-32.2	-36.1	-29.7	-27.0	-29.1	-33.5	-31.8	-40.2	-40.5	-53.6	-38.8	-47.0	-34.0	-36.4	-41.1	-29.3	-29.4	-40.7	-29.1	-25.2	-18.8	-40.4	-23.3	-26.6	-25.4	-44.2	-9.15
Investing	-0.02	—	—	-5.21	0.1	-8.02	2.98	6.44	-111	20.6	16.4	-136	12.3	23.5	46.1	41.5	-139	28.9	32.9	34.9	61.9	-146	13.5	62.8	7.25	72.5	36.0	-39.7	-40.8	18.5	48.2	-95.0	22.6	30.1	-8.56	-90.8	21.2	24.8	54.0	-246	30.4	57.0	14.0
Financing	41.7	—	—	—	—	20.4	0	21.2	126	—	163	1.17	0.15	0.32	0.5	0.7	162	0.71	0.18	0.7	0.42	166	0.38	0.41	0.1	0.4	37.5	159	17.4	-0.13	-0.96	73.0	2.42	4.24	146	2.49	38.3	32.5	-0.89	189	-2.95	-5.40	-1.16
Cash at period end	34.9	—	—	12.6	6.54	12.1	8.95	27.9	34.2	43.2	210	58.3	49.5	42.0	63.1	71.7	62.3	55.8	59.1	67.7	101	87.3	69.3	92.4	59.3	78.5	113	185	128	110	116	64.6	60.1	53.4	162	47.5	89.1	106	136	52.1	54.3	62.1	65.6

Profitability

Quarterly · %

Operating margin -68.1% Net margin -69.2%

Gross, operating and net margin = the respective profit ÷ revenue.

Show table：Profitability

Item	2015Q4	2016Q1	2016Q2	2016Q3	2016Q4	2017Q1	2017Q2	2017Q3	2017Q4	2018Q1	2018Q2	2018Q3	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2
Operating margin	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	-98280.0%	-14756.2%	-4303.5%	-2806.2%	-3517.4%	-497.4%	-916.6%	-479.0%	-458.0%	-242.5%	-195.3%	-170.3%	-538.7%	-139.2%	-132.0%	-98.6%	-143.7%	-93.4%	-102.6%	-82.2%	-87.1%	-68.1%
Net margin	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	125000.0%	-12915.7%	-3415.1%	-2359.2%	-3522.3%	-496.4%	-953.8%	-483.4%	-455.0%	-243.0%	-196.3%	-171.8%	-544.4%	-111.0%	-131.3%	-103.5%	-151.3%	-96.1%	-103.1%	-83.0%	-92.6%	-69.2%

Returns & leverage

Quarterly · %

ROE -450.9% ROA -50.7% Debt ratio 50.3%

ROE / ROA = trailing four-quarter net income ÷ average equity / total assets (annual mode: the year’s net income ÷ average of opening and closing). Not computed when the denominator is zero or negative.

Show table：Returns & leverage

Item	2015Q4	2016Q1	2016Q2	2016Q3	2016Q4	2017Q1	2017Q2	2017Q3	2017Q4	2018Q1	2018Q2	2018Q3	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2
ROE	—	—	—	—	—	—	—	—	-60.1%	-32.8%	-18.1%	-54.3%	-37.9%	-48.9%	-49.4%	-63.7%	-53.4%	-61.6%	-65.9%	-76.3%	-59.9%	-17.7%	-20.9%	-23.8%	-30.9%	-53.9%	-64.2%	-60.1%	-66.0%	-79.3%	-96.4%	-77.5%	-85.1%	-194.7%	-234.1%	-248.1%	-272.1%	-419.0%	-1334.5%	-240.4%	-244.4%	-285.8%	-450.9%
ROA	—	—	—	—	-209.7%	—	—	-90.6%	-41.1%	-31.4%	-17.6%	-37.8%	-36.0%	-46.1%	-45.7%	-58.5%	-49.5%	-57.2%	-59.1%	-67.2%	-54.1%	-16.1%	-19.1%	-21.6%	-26.9%	-47.0%	-52.8%	-48.7%	-50.9%	-57.3%	-62.0%	-49.9%	-51.6%	-90.6%	-75.0%	-72.1%	-71.9%	-52.3%	-48.5%	-44.2%	-45.0%	-48.9%	-50.7%
Debt ratio	—	—	—	—	40.9%	—	—	16.4%	4.6%	4.2%	2.5%	2.9%	5.4%	6.8%	13.9%	16.0%	8.9%	7.5%	7.3%	8.6%	11.0%	9.8%	9.4%	9.4%	13.8%	17.2%	29.6%	27.8%	30.9%	36.4%	41.2%	44.3%	49.0%	76.2%	53.0%	58.0%	58.0%	57.8%	64.2%	41.7%	43.8%	46.3%	50.3%

EPS

Quarterly · US$

EPS US$-0.73

Show table：EPS

Item	2015Q4	2016Q1	2016Q2	2016Q3	2016Q4	2017Q1	2017Q2	2017Q3	2017Q4	2018Q1	2018Q2	2018Q3	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2
EPS（US$）	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	-3.86	-0.78	-0.71	—	-1.56	0.90	-0.70	-0.70	-0.86	-1.05	-0.89	-0.79	-0.74	-0.92	-0.82	-0.76	-0.70	-2.35	-0.55	-0.73	-0.72	-0.81	-0.75	-0.82	-0.73	-0.83	-0.73

Revenue & profit

Year-to-date · In mn (USD)

Revenue 131 mn Net income -105 mn

Year-to-date = summed from the first quarter of the fiscal year; balance-sheet items are period-end balances.

Balance sheet

Year-to-date · In mn (USD)

Total assets 437 mn Total liabilities 220 mn

Equity = assets − liabilities. Balance-sheet figures are period-end balances, not cumulative.

Cash flow

Year-to-date · In mn (USD)

Operating -53.3 mn Investing 71.1 mn Financing -6.56 mn

Positive = cash in, negative = cash out.

Profitability

Year-to-date · %

Operating margin -76.8% Net margin -79.9%

Gross, operating and net margin = the respective profit ÷ revenue.

Returns & leverage

Year-to-date · %

ROE -450.9% ROA -50.7% Debt ratio 50.3%

EPS

Year-to-date · US$

EPS US$-1.56

Revenue & profit

Annual · In mn (USD)

Revenue 190 mn Net income -197 mn

Annual = sum of four quarters of a complete fiscal year (incomplete years are omitted); balance-sheet items are year-end balances.

Show table：Income statement

Item	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Revenue	—	—	—	—	—	3.15	23.6	77.4	130	190
Operating income	—	-32.4	-78.4	-146	-137	-170	-179	-184	-265	-192
Net income	-25.9	-33.7	-74.1	-141	-134	-69.6	-181	-185	-261	-197

Balance sheet

Annual · In mn (USD)

Total assets 480 mn Total liabilities 210 mn

Equity = assets − liabilities. Balance-sheet figures are period-end balances, not cumulative.

Show table：Balance sheet

Item	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Current assets	11.2	151	259	302	182	308	354	308	374	467
Total assets	12.3	152	260	309	187	330	382	333	392	480
Current liabilities	4.73	6.72	13.6	24.4	18.0	43.4	39.8	55.2	116	106
Total liabilities	5.04	6.95	13.9	27.5	20.6	45.4	118	163	228	210
Equity	-32.7	145	246	281	167	284	264	170	21.7	139

Cash flow

Annual · In mn (USD)

Operating -116 mn Investing -137 mn Financing 218 mn

Positive = cash in, negative = cash out.

Show table：Cash flow statement

Item	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Operating	—	-29.5	-62.1	-123	-122	-146	-173	-136	-114	-116
Investing	—	-110	-87.2	-28.0	159	-62.2	28.0	-5.66	-48.2	-137
Financing	—	167	—	163	2.01	166	214	74.4	191	218
Cash at period end	6.54	34.2	49.5	62.3	101	59.3	128	60.1	89.1	54.3

Profitability

Annual · %

Operating margin -101.2% Net margin -103.6%

Gross, operating and net margin = the respective profit ÷ revenue.

Show table：Profitability

Item	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Operating margin	—	—	—	—	—	-5391.9%	-757.9%	-238.1%	-204.0%	-101.2%
Net margin	—	—	—	—	—	-2207.1%	-766.2%	-238.5%	-200.2%	-103.6%

Returns & leverage

Annual · %

ROE -244.4% ROA -45.0% Debt ratio 43.8%

Show table：Returns & leverage

Item	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
ROE	—	-60.1%	-37.9%	-53.4%	-59.9%	-30.9%	-66.0%	-85.1%	-272.1%	-244.4%
ROA	-209.7%	-41.1%	-36.0%	-49.5%	-54.1%	-26.9%	-50.9%	-51.6%	-71.9%	-45.0%
Debt ratio	40.9%	4.6%	5.4%	8.9%	11.0%	13.8%	30.9%	49.0%	58.0%	43.8%

EPS

Annual · US$

EPS US$-3.11

Show table：EPS

Item	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
EPS（US$）	—	—	—	—	—	-1.36	-3.47	-3.20	-4.35	-3.11

Source: SEC EDGAR (XBRL company facts)

Annual reports by year

	10-K
2025	Open full text →
2024	Open full text →
2023	Open full text →

10-K: annual report of a US domestic issuer. Filings are the original documents hosted on SEC EDGAR — this site neither mirrors nor edits them.

FAQ

Where can I read RHYTHM PHARMACEUTICALS, INC. (RYTM) annual reports?

Every year in the table above links straight to the full text on SEC EDGAR. US annual reports are web pages (HTML) rather than PDFs, so you can read and search them in the browser without downloading anything. 3 filings are currently indexed.

What is the difference between a 10-K and a 20-F?

A 10-K is the annual report of a US domestic issuer, with sections fixed by law: Item 1 Business, Item 1A Risk Factors, Item 7 Management's Discussion and Analysis. A 20-F is filed by foreign private issuers — Taiwanese companies with US ADRs, such as TSMC, file 20-F rather than 10-K. A 40-F applies to Canadian issuers under the MJDS.

Are earnings call materials available here?

No. Earnings calls are not SEC filings, so US pages on this site cover annual reports only. Taiwan has a mandatory investor-conference disclosure regime, and those materials are indexed under Annual Reports.

Source: US Securities and Exchange Commission (SEC) EDGAR. This site indexes public filings and links to them; it hosts no copies, offers no investment advice, and makes no warranty as to timeliness or completeness.
Back to US annual reports, or see the supply-chain maps.